Rituximab is successful in an HIV-positive patient with MuSK myasthenia gravis

Neurology. 2011 Feb 22;76(8):757-8. doi: 10.1212/WNL.0b013e31820d6290.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies / blood
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use*
  • Female
  • HIV Seropositivity / complications
  • HIV Seropositivity / drug therapy*
  • HIV Seropositivity / immunology
  • Humans
  • Immunologic Factors / therapeutic use*
  • Myasthenia Gravis / complications
  • Myasthenia Gravis / drug therapy*
  • Myasthenia Gravis / immunology
  • Receptor Protein-Tyrosine Kinases / immunology
  • Receptors, Cholinergic / immunology
  • Rituximab
  • Young Adult

Substances

  • Antibodies
  • Antibodies, Monoclonal, Murine-Derived
  • Immunologic Factors
  • Receptors, Cholinergic
  • Rituximab
  • MUSK protein, human
  • Receptor Protein-Tyrosine Kinases